Shampa Das

Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression

Carola A. Neumann, Daniela S. Krause, Christopher V. Carman et al. · Nature · 2003 · 795 citations · Full text

Life Sciences, Biochemistry, Cancer Biology +17

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

David P. Nicolau, Leonard Siew, J. Armstrong et al. · Journal of Antimicrobial Chemotherapy · 2015 · 129 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +14

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

David S. Boss, Petronella O. Witteveen, J. van der Sar et al. · Annals of Oncology · 2010 · 109 citations · Full text

Medicine, Oncology, Pharmacology +17

Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups

Jianguo Li, Mark Lovern, Michelle Green et al. · Clinical and Translational Science · 2018 · 100 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors

Gary K. Schwartz, Richard D. Carvajal, Rachel Midgley et al. · Investigational New Drugs · 2012 · 80 citations

Medicine, Oncology, Pharmacology +10